Health Related Quality of Life Following Hepatectomy for Colorectal Liver Metastasis: Global and Disease Specific Changes Over Time

NCT02399995 | Active Not Recruiting

• 1 other identifier: 15-057
• Study Type: observational
• Target: 219
• Locations: 1 country
• Sites: 7

Brief Summary

This study is being done to learn more about health related quality of life factors in people having surgery for colorectal liver metastasis. The investigators will look at how these factors may change over time. The information gained from this study will help the investigators to understand the long-term effects that cancer treatments have on the health related quality of life of patients. This information is of high value and will help doctors talk to patients about the possible effects of their operations. While many patients live a long time after such operations, the studies that have been done do not tell the full story of what patients go through after surgery. This study will help us to understand cancer treatment from the patient's perspective. It will also help cancer patients make better decisions about their treatment options and will help them know what to expect after the operation.

Conditions

Colorectal Liver Metastasis

Keywords

Quality of Life; Hepatectomy; 15-057

Outcome Measures

Primary Outcomes (1)

• changes in the quality of life (QoL)

  in patients at high risk of recurrence undergoing hepatectomy to assess health related quality of life (HRQoL) using the EORTC QLQ-C30, QLQ-LMC21 and the EuroQol EQ-5D-5L, in patients at high risk of recurrence undergoing hepatectomy for colorectal liver metastasis and to evaluate global and disease specific changes over time.

  3 years

Study Arms (1)

patients following hepatectomy

Behavioral: HRQoL questionnaires.

Interventions

HRQoL questionnaires. BEHAVIORAL

Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator: * Baseline sociodemographic and clinical variable data sheet (RSA) * EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS * Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit: * EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy: * EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS * Post surgical follow up disease status and treatment assessment questionnaire * At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone.

patients following hepatectomy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients scheduled to undergo liver resection who meet the established criteria will be approached for participation in this study during their preoperative visit. Should patients not undergo their liver resection surgery within 30 days of consent they will be excluded and replaced. Patients undergoing a two stage resection will have their time point frozen for up to six months after their initial surgery. If the time before the second stage of their resection exceeds six months, these patients will be excluded and replaced. The time point will restart at the completion of the second time point. If the patient has an incomplete resection without mention of a second stage resection, the patient will be made ineligible, taken off study, and replaced.

You may qualify if:

• Diagnosis of Colorectal cancer liver metastases (CRLM)
• \> 18 years of age
• Absence of unresectable extrahepatic disease
• No previous liver surgery for CRLM
• Clinical risk score (CRS) \>/= 3 or \> 4 tumors
• CRS includes the following variables;
• Lymph node positive primary
• Disease free interval \<12 months
• CEA level \>200ng/mL (highest CEA level within 6 months prior to surgery, not including day of surgery)
• Tumor size \> 5cm
• Number of tumors \>1(based on most recent scan or pathology before liver resection)
• Each variable is given a score of one and summed to give final CRS
• Clinical risk score (CRS) \< 3 with pending variables that cannot be determined preoperatively
• If CRS is still \< 3 postoperatively, these patients will be excluded and replaced (inevaluable).
• Ability to read and write in English

You may not qualify if:

• Non-English speaking
• Inability to read and/or write
• International Patients
• Concurrent malignancy (excluding non-melanoma skin cancers)

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead

Study Sites (7)

Memorial Sloan Kettering Basking Ridge (Consent and Follow up)

Basking Ridge, New Jersey, United States

Location

Memorial Sloan Kettering Monmouth (Consent and Follow up)

Middletown, New Jersey, 07748, United States

Location

Memorial Sloan Kettering Bergen (Consent and Follow up)

Montvale, New Jersey, 07645, United States

Location

Memorial Sloan Kettering Commack (Consent and Follow up)

Commack, New York, 11725, United States

Location

Memorial Sloan Kettering Westchester (Consent and Follow Up)

Harrison, New York, 10604, United States

Location

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States

Location

Memorial Sloan Kettering Nassau (Consent and follow up)

Uniondale, New York, 11553, United States

Location

Related Links

• Memorial Sloan Kettering Cancer Center

Study Officials

• Michael D'Angelica, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 23, 2015
• First Posted: March 26, 2015
• Study Start: March 1, 2015
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): March 1, 2027
• Last Updated: April 14, 2026

Record last verified: 2026-04

Locations

US (7)